bluebird bio (BLUE) : bluebird bio (BLUE) had a healthy money flow of $0.87 million into the stock during the Thursdays trading session. The value of bullish trades on upticks was $2.99 million, whereas, investors only sold shares worth $2.12 million on downticks. The stock closed the day with an up-down ratio of 1.41.The money flow in the block trades to the tune of $0.1 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $0.1 million worth of transactions were on upticks. bluebird bio (BLUE) stock slid $0.03 intraday and traded at 46.49, a change of -0.06% over previous days close. However, for the week, the company shares are -4.64% compared to previous weeks close.
The stock has recorded a 20-day Moving Average of 4.91% and the 50-Day Moving Average is 6.92%. Shares have dropped -70.71% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $171.24 and the one year low was seen on May 12, 2016. The 50-Day Moving Average price is $43.57 and the 200 Day Moving Average price is recorded at $46.19.
bluebird bio (NASDAQ:BLUE): The stock opened at $47.04 on Thursday but the bulls could not build on the opening and the stock topped out at $47.53 for the day. The stock traded down to $45.26 during the day, due to lack of any buying support eventually closed down at $45.55 with a loss of -2.09% for the day. The stock had closed at $46.52 on the previous day. The total traded volume was 705,739 shares.
In an insider trading activity,The officer (Chief Medical Officer) of Bluebird Bio, Inc., Davidson David sold 1,000 shares at $40.11 on June 15, 2016. The Insider selling transaction had a total value worth of $40,110. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.